U.S. patent number RE48,536 [Application Number 16/364,805] was granted by the patent office on 2021-04-27 for collagen sponge.
This patent grant is currently assigned to Geistlich Pharma. The grantee listed for this patent is Geistlich Pharma AG. Invention is credited to Cornel Imhof, Lothar Schloesser, Niklaus Stiefel, Martin Wuest.


United States Patent |
RE48,536 |
Imhof , et al. |
April 27, 2021 |
Collagen sponge
Abstract
A resilient resorbable chemically crosslinked collagen sponge
for promoting soft tissue volume augmentation in the oral region,
comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which
shows by mercury intrusion porosimetry interconnected pores with a
median pore diameter between 50 and 90 .mu.m and at least 80%
porosity with a pore diameter more than 10 .mu.m, an onset
temperature of 45 to 57.degree. C. and a density in dry state from
50 to 65 mg/cm.sup.3. A process for preparing a resilient
resorbable chemically crosslinked collagen sponge. A method of
using a resilient resorbable chemically crosslinked collagen sponge
as an implant in the oral cavity for soft tissue volume
augmentation.
Inventors: |
Imhof; Cornel (Lucerne,
CH), Schloesser; Lothar (Lucerne, CH),
Stiefel; Niklaus (Lucerne, CH), Wuest; Martin
(Emmenbrucke, CH) |
Applicant: |
Name |
City |
State |
Country |
Type |
Geistlich Pharma AG |
Wolhusen |
N/A |
CH |
|
|
Assignee: |
Geistlich Pharma (Wolhusen,
CH)
|
Family
ID: |
52023367 |
Appl.
No.: |
16/364,805 |
Filed: |
March 26, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
Reissue of: |
14969158 |
Dec 15, 2015 |
9655997 |
May 23, 2017 |
|
|
Foreign Application Priority Data
|
|
|
|
|
Dec 15, 2014 [EP] |
|
|
14197987 |
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61L
27/362 (20130101); A61L 27/26 (20130101); A61L
27/3683 (20130101); A61L 27/3687 (20130101); A61L
27/56 (20130101); A61L 27/3629 (20130101); A61L
27/3625 (20130101); A61L 27/3604 (20130101); A61L
27/3691 (20130101); A61L 2430/34 (20130101) |
Current International
Class: |
A61L
27/56 (20060101); A61L 27/26 (20060101); A61L
27/36 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
1561480 |
|
Aug 2005 |
|
EP |
|
1676592 |
|
Jul 2006 |
|
EP |
|
1676592 |
|
Jan 2013 |
|
EP |
|
3055000 |
|
Dec 2016 |
|
EP |
|
2012084214 |
|
Jun 2012 |
|
WO |
|
Other References
Boekema et al., "Effect of pore size and cross-linking of a novel
collagen-elastin dermal substitute on wound healing" Journal of
Material Sciences: Materials in Medicine, vol. 25, (2014), pp.
423-433, XP002740386. cited by applicant .
Cairo et al. "Treatment of gingival recession with coronally
advanced flap procedures: a systematic review" J. Clin.
Periodontal. 35 (Suppl. 8) (2008), pp. 136-162 (abstract). cited by
applicant .
Jung et al. "Postextraction tissue management: a soft tissue punch
technique" Int J Periodontics Restorative Dent 24(6) (2004) pp.
545-553. (Abstract). cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority issued in International
Application No. PCT/EP2015/079754, dated Jun. 20, 2017, 12 pages.
cited by applicant .
Intention to Grant Communication Under Rule 71(3) EPC issued in
corresponding European Application No. 15808663.7, dated Sep. 28,
2016, 36 pages. cited by applicant .
Notice of Allowance in corresponding Canadian Application
CA2,970,849, dated Feb. 6, 2019, 1 page. cited by applicant .
Notification of Grant in corresponding Singapore application No.
11201704864Y, dated Jul. 4, 2018, 2 pages. cited by applicant .
Notice of Acceptance in corresponding Australian application No.
2015367710, Jul. 2, 2018, 3 pages. cited by applicant .
Cairo et al. "Soft Tissue Management at implant sites" J. Clin.
Periodontol. 35 (Suppl. 8) (2008), pp. 163-167 (abstract). cited by
applicant .
Extended European Search Report in application No. EP14197987.2
dated Jun. 26, 2015. cited by applicant .
Hafemann et al. "Cross-linking by 1-ethyl-3
(3-dimethylaminopropyl)-carbodiimide (EDC) of a collagen/elastin
membrane meant to be used as a dermal substitute: effects on
physical, biochemical and biological features in vitro", Journal of
Materials Science: Materials in Medicine, vol. 12, No. 5, 1 (2001),
pp. 437-446, XP055193133. cited by applicant .
Mathes et al. "A bioreactor test system to mimic the biological and
mechanical environment of oral soft tissues and to evaluate
substitutes for connective tissue grafts" Biotechnology and
Bioengineering, vol. 107, No. 6, 15 (2010), pp. 1029-1039,
XP055191964. cited by applicant .
Thoma et al. "Soft tissue volume augmentation by the use of
collagen-based matrices in the dog mandible: a histological
analysis." J. Clin. Periodontol.: 38: (2011), pp. 1063-1070
(Abstract). cited by applicant .
Thoma et al. "A systematic review assessing soft tissue
augmentation techniques" Clin. Oral Impl. Res. 20 (Supp. 4) 2009,
pp. 146-165. cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority issued in International
Application No. PCT/EP2015/079754, dated Feb. 12, 2016, 14 pages.
cited by applicant .
Intention to Grant Communication Under Rule 71(3) EPC issued in
corresponding European Application No. 15808663.7, dated Sep. 28,
2016, 37 pages. cited by applicant.
|
Primary Examiner: Orwig; Kevin S
Attorney, Agent or Firm: Rothwell, Figg, Ernst &
Manbeck, P.C.
Claims
The invention claimed is:
1. A resilient resorbable chemically crosslinked collagen sponge
for promoting soft tissue volume augmentation in an oral cavity,
comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which
shows by mercury intrusion porosimetry interconnected pores with a
median pore diameter between 50 and 90 .mu.m and at least 80%
porosity with a pore diameter more than 10 .mu.m, an onset
temperature of 45 to 57.degree. C. and a density in dry state from
50 to 65 mg/cm.sup.3.
2. The resilient resorbable chemically crosslinked collagen sponge
of claim 1 which shows an onset temperature from 46 to 53.degree.
C.
3. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which shows a density in dry state from 50 to 60
mg/cm.sup.3.
4. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which comprises 70-90% (w/w) collagen and 10-30% (w/w)
elastin.
5. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which shows at least 90% porosity with a pore diameter
more than 10 .mu.m.
6. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which was obtained using a cross-linking agent selected
from the group consisting of gluteraldehyde, EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and a mixture of
EDC and NHS (N-hydoxysuccinimide).
7. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which was derived from tissues of natural origin by a
process comprising freeze drying and chemical crosslinking,
optionally followed by .gamma.-sterilization or X-ray
sterilization.
8. The resilient resorbable chemically crosslinked collagen sponge
of claim 7, wherein the tissues of natural origin include porcine
or bovine peritoneum or pericardium membranes, porcine or bovine
placenta membrane, or porcine or bovine SIS or dermis.
9. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which wetted by a PBS solution retains at least 70% of
initial thickness after 49 cycles of compression to a pressure of
12.1 kPa.
10. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which wetted by a PBS solution retains less than 55%
hysteresis with respect to the first loading after 49 cycles of
compression to a pressure of 12.1 kPa.
11. The resilient resorbable chemically crosslinked collagen sponge
of claim 1, which shows after implantation in the oral cavity the
same volume retention as SCTG (Subepithelial Connective Tissue
Graft).
12. A process for making the resilient resorbable chemically
crosslinked collagen sponge of claim 1, which comprises the
following steps: (a) submitting a porcine or bovine peritoneum or
pericardium membrane to a basic treatment in a sodium hydroxide
solution at a pH above 12, an acid treatment in a hydrochloric
solution of pH of 1 to 3, a dehydrating treatment with a water
soluble organic solvent and a degreasing treatment with an organic
solvent, milling the dry membrane obtained with a cutting mill,
sieving through a 0.5-2 mm sieve and suspending the powder obtained
in an acidified water solution of pH from 2.5 to 3.5, .[.such as.].
to obtain a first slurry of collagen fibres, (b) .Iadd.separately
from step (a) .Iaddend.submitting grinded bovine or porcine dermis
to a dehydrating treatment with a water soluble organic solvent, a
degreasing treatment with an organic solvent, a basic treatment in
a strong inorganic base at a pH above 12, an acid treatment in a
strong inorganic acid at a pH from 0 to 1, rinsing with water and
suspending the collagen fibres, freeze-drying, cleaning the dried
collagen fibres with an organic solvent and grinding the cleaned
dried fibres in an acidified solution of pH from 3 to 4, .[.such
as.]. to obtain a second slurry of collagen fibres, (c) mixing 3.5
to 4.5 parts of the collagen fibres slurry obtained in (a) with 0.5
to 1.5 parts of the collagen fibres slurry obtained in (b), .[.such
as.]. to obtain a resulting slurry, (d) freeze-drying the resulting
slurry obtained in (c) to obtain a first freeze-dried product, and
crosslinking the first freeze-dried product in a solution
containing a crosslinking agent, washing with water and
freeze-drying to obtain a second freeze-dried product, and (e)
optionally sterilizing the second freeze-dried product obtained in
(d) by .gamma. irradiation or X-ray irradiation.
13. The process according to claim 12, wherein the crosslinking
agent is selected from the group consisting of gluteraldehyde, EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and a mixture of
EDC and NHS (N-hydoxysuccinimide).
14. The process according to claim 12, wherein the slurry of
collagen fibres prepared in step (a) contains 2.5 to 3.75 (w/w) %
collagen and the slurry of collagen fibres prepared in step (b)
contains from 4.0 to 6.0 (w/w) % collagen.
15. A method of promoting soft tissue volume augmentation in an
oral cavity of a subject in need thereof, comprising implanting the
resilient resorbable chemically cross-linked collagen sponge of
claim 1 into said subject's oral cavity to promote tissue volume
augmentation.
.Iadd.16. An implant comprising a sterile resilient resorbable
chemically crosslinked collagen sponge that is resistant to cyclic
compression, comprising 60-96% (w/w) collagen and 4-40% (w/w)
elastin, which shows by mercury intrusion porosimetry
interconnected pores with a median pore diameter between 50 and 90
.mu.m and at least 80% porosity with a pore diameter more than 10
.mu.m, an onset temperature of 45 to 57.degree. C. and a density in
dry state from 50 to 65 mg/cm.sup.3..Iaddend.
.Iadd.17. The implant of claim 16, wherein the sterile resilient
resorbable chemically crosslinked collagen sponge has an onset
temperature from 46 to 53.degree. C..Iaddend.
.Iadd.18. The implant of claim 16, wherein the sterile resilient
resorbable chemically crosslinked collagen sponge has a density in
dry state from 50 to 60 mg/cm.sup.3..Iaddend.
.Iadd.19. The implant of claim 16, wherein the sterile resilient
resorbable chemically crosslinked collagen sponge comprises 70-90%
(w/w) collagen and 10-30% (w/w) elastin..Iaddend.
.Iadd.20. The implant of claim 16, wherein the sterile resilient
resorbable chemically crosslinked collagen sponge has at least 90%
porosity with a pore diameter more than 10 .mu.m..Iaddend.
.Iadd.21. The implant of claim 16, wherein the sterile resilient
resorbable chemically crosslinked collagen was obtained using a
crosslinking agent selected from the group consisting of
gluteraldehyde, EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and a mixture of
EDC and NHS (N-hydoxysuccinimide)..Iaddend.
.Iadd.22. The implant of claim 16, wherein the sterile resilient
resorbable chemically crosslinked collagen sponge was derived from
tissues of natural origin by a process comprising freeze drying and
chemical crosslinking, optionally followed by .gamma.-sterilization
or X-ray sterilization..Iaddend.
.Iadd.23. The implant of claim 22, wherein the tissues of natural
origin include porcine or bovine peritoneum or pericardium
membranes, porcine or bovine placenta membrane, or porcine or
bovine SIS or dermis..Iaddend.
.Iadd.24. The implant of claim 16, when wetted by a PBS solution
retains at least 70% of initial thickness after 49 cycles of
compression to a pressure of 12.1 kPa..Iaddend.
.Iadd.25. The implant of claim 16, when wetted by a PBS solution
retains less than 55% hysteresis with respect to the first loading
after 49 cycles of compression to a pressure of 12.1
kPa..Iaddend.
.Iadd.26. The implant of claim 16, having properties such that the
collagen completely degrades within 3 to 5 hours in an enzymatic
degradation test using collagenase from Clostridium
histolyticum..Iaddend.
.Iadd.27. The implant of claim 16, wherein the sterile resilient
resorbable chemically crosslinked collagen sponge comprises 70-90%
(w/w) collagen and 10-30% (w/w) elastin, which shows by mercury
intrusion porosimetry interconnected pores with a median pore
diameter between 50 and 90 .mu.m and at least 90% porosity with a
pore diameter more than 10 .mu.m, an onset temperature of 46 to
53.degree. C. and a density in dry state from 50 to 60
mg/cm.sup.3..Iaddend.
Description
This application claims the benefit of European Patent Application
No. 14197987.2 filed on Dec. 15, 2014, the disclosure of which is
incorporated by reference in its entirety.
FIELD OF THE INVENTION
The invention relates to a new resilient resorbable chemically
crosslinked collagen sponge for promoting soft tissue volume
augmentation in the oral region, a process for preparing that
resilient resorbable chemically crosslinked collagen sponge and the
use thereof as an implant in the oral cavity for soft tissue volume
augmentation.
BACKGROUND OF THE INVENTION
Soft tissue volume augmentation has become one of the major
challenges in dental and cranio-maxillofacial surgery. In order to
improve both functional and esthetic outcomes by soft tissue volume
augmentation, autogenous tissue grafts such as the free gingival
graft (FGG) or the subepithelial connective tissue graft (SCTG),
despite their drawbacks are still broadly used for various
indications and considered to be the gold standard (F. Cairo et
al., 2008, J. Clin. Periodontol. 35 (Suppl. 8), 314-319; R. Jung et
al., 2004, Int. J. Periodontics Restorative Dent. 24(6), 545-553
and D. Thoma, 2009, Clin. Oral Implants Res. 20 (suppl. 4),
146-165). However, the harvesting procedure for autogenous tissue
at a second surgical site usually in the palate has drawbacks for
the patient and limitations as to the quality and quantity of
tissue that can be retrieved.
A regenerative device for promoting soft tissue volume augmentation
in the oral region is thus desirable.
Gingival cells of the oral connective tissue are exposed to complex
mechanical forces during mastication, swallowing, tongue movement,
speech, tooth movement and orthodontic treatment. Especially during
wound healing following surgical procedures, internal and external
forces may occur, creating pressure upon the regenerative device
and newly formed tissue.
A regenerative device has to meet certain criteria before being
used in the oral cavity for soft tissue volume augmentation: It
must be biocompatible, resorbable in vivo, allow gingival ingrowth,
show a good level of tissue integration such as to allow uneventful
healing (without excessive inflammation or dehiscence) and be able
to withstand mechanical forces by acting as a scaffold that
maintains tissue volume during a sufficient time during the wound
healing process after implantation, generally at least about 3
months.
No such regenerative device has so far been disclosed in the prior
art.
H. Mathes et al. in "A Bioreactor Test System to mimic the
Biological and Mechanical Environment of Oral Soft Tissues and to
Evaluate Substitutes for Connective Tissue Gaffs", 2010,
Biotechnology and Bioengineering, Vol. 9999, No. 9999, disclose
that such properties of a regenerative device consisting of a
collagen sponge might be achieved by stiffening the matrix body by
crosslinking of the collagen fibers to a degree allowing the right
balance between mechanical stability (high degree of crosslinking)
and uneventful soft tissue healing (low degree of crosslinking),
but are totally silent on how to prepare such a collagen sponge.
They disclose that three different collagen sponge prototypes
consisting of porcine collagen type I and Ill with an average pore
diameter of 92 .mu.m and 93% porosity and differing in their degree
of crosslinking (prototypes provided by Geistlich Pharma, Wolhusen,
Switzerland) showed after culture under mechanical stimulation for
14 days a satisfying volume retention with a good fibroblast cell
vitality.
DS Thoma et al. in "Soft tissue volume augmentation by the use of
collagen-based matrixes: a volumetric analysis", 2010, J. of Clin.
Periodontology 37, 659-666, and "Soft tissue volume augmentation by
the use of collagen-based matrixes in a dog mandible--a
histological analysis", 2011, J. Clin. Periodontol.: 38:1063-1070,
disclose that one of the collagen sponge prototypes referred to in
the above publication of H. Mathes et al. showed after a period of
28 or 84 days of implementation into a chronic ridge defect of a
dog mandible the same volume retention as the gold standard, SCTG
(subendopithelial connective tissue graft).
The prior art does not disclose or suggest what are the features of
such a chemically crosslinked collagen sponge prototype, or of any
other regenerative collagen device fulfilling the criteria set
forth above for a use in the oral cavity for soft tissue volume
augmentation, or how such a device can be prepared.
EP-1561480 discloses a resorbable collagen device for use as a
dural substitute for growing meningeal tissue, comprising a
chemically crosslinked collagen sheet which has a majority of pores
below 10 .mu.m and a method for preparing that collagen device
comprising the steps of mixing collagen with water under such
conditions that the mixture contains substantially solubilized
collagen, lyophilizing the mixture into a collagen device and
chemically crosslinking the collagen device, using as crosslinking
agent formaldehyde or gluteraldehyde. A dural substitute is not,
like a regenerative device for promoting soft tissue volume
augmentation in the oral region, exposed during wound healing to
pressure created by the above mentioned complex mechanical
forces.
US-2004-0265785 describes a process for producing a
collagen-elastin membrane containing at least 20% (w/w) elastin,
comprising the steps of first chemically removing hydrophobic
accompanying substances from an elastin containing collagen
material of natural origin, then chemically removing
non-hydrophobic substances. The collagen-elastin product is not
chemically crosslinked.
Boekema B. K. L. H. et al., 2014, Journal of Material Sciences:
Materials in Medicine, Feb. 2014 25: 423-433, describe the effect
on wound healing of pore size and crosslinking on collagen-elastin
scaffolds used as dermal substitutes. The disclosed EDC-NHS
chemically crosslinked scaffolds contain 10-15% elastin, have a
pore size of 80 to 120 .mu.m and a denaturation temperature of 64
to 69.degree. C. (see Table 1, page 425). They are sterilized by
ethylene oxide gas treatment. The authors conclude that
crosslinking negatively affects wound healing on several important
parameters, notably by reducing the ability of fibroblasts to
proliferate and replace the dermal substitute by new tissue. A
dermal substitute is not, like a regenerative device for promoting
soft tissue volume augmentation in the oral region, exposed during
wound healing to pressure created by the above mentioned complex
mechanical forces.
The problem or objective of the invention is to find a regenerative
collagen device for promoting soft tissue volume augmentation in
the oral region that is biocompatible, resorbable in vivo, allows
gingival ingrowth, shows a good level of tissue integration such as
to allow uneventful healing (without excessive inflammation or
dehiscence) and be able to withstand mechanical forces by acting as
a scaffold that maintains tissue volume during a sufficient time
during the wound healing process after implantation, generally at
least about 3 months.
The above problem is solved by the invention as defined in the
appended claims.
BRIEF SUMMARY OF THE INVENTION
The invention relates to a resilient resorbable chemically
crosslinked collagen sponge for promoting soft tissue volume
augmentation in the oral region, comprising 60-96% (w/w) collagen
and 4-40% (w/w) elastin, which shows by mercury intrusion
porosimetry interconnected pores with a median pore diameter
between 50 and 90 .mu.m and at least 80% porosity with a pore
diameter more than 10 .mu.m, an onset temperature of 45 to
57.degree. C. and a density in dry state from 50 to 65
mg/cm.sup.3.
The chemically crosslinked collagen sponge comprises 60-96% (w/w)
collagen and 4-40% (w/w) elastin. The elastin content is here
measured by desmosine/iodesmosine determination according to a
modification of a known method involving hydrolysis and RP-HPLC
(see e.g. Guida E. et al. 1990 Development and validation of a high
performance chromatography method for the determination of
desmosines in tissues in Journal of Chromatography or Rodriguqe P
2008 Quantification of Mouse Lung Elastin During Prenatal
Development in The Open Respiratory Medicine Journal). To determine
the desmosine/isodesmosine content of dry elastin, the elastin of
the sponge is subjected to elastin isolation procedures as
described by Starcher and Galione 1976 Purification and Comparison
of Elastin from Different Animal Species in Analytical
Biochemistry.
That sponge is suitably derived from tissues of natural origin
which contain such proportions of collagen and elastin. Examples of
such tissues include mammalian (e.g. porcine or bovine) peritoneum
or pericardium membrane, placenta membrane, small intestine
submucosa (SIS) and dermis. Usually the collagen is predominantly
collagen type I, collagen type III or a mixture thereof. The
collagen may also include a proportion of notably collagen type II,
type IV, type VI or type VIII or any combination of those or any
collagen types.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING
The FIGURE shows the typical result of a cyclic compression
test.
DETAILED DESCRIPTION OF THE INVENTION
The term "collagen" used in this application usually refers to that
combination of 60-96% (w/w) collagen and 4-40% (w/w) elastin.
Preferably the chemically crosslinked collagen sponge comprises
70-90% (w/w) collagen and 10-30% (w/w) elastin.
An example of a suitable starting material for preparing such a
chemically crosslinked collagen sponge is a slurry of collagen
fibres from the membrane prepared from porcine or bovine peritoneum
by a process similar to that described in "Example" of
EP-B1-1676592 or from the membrane Geistlich Bio-Gide.RTM.
(obtainable from Geistlich Pharma A.G., Switzerland) prepared from
porcine peritoneum by a very similar process and/or a slurry of
collagen fibres prepared from porcine dermis by a process similar
to that described in Example 7 of WO 2012/084214.
The above resilient resorbable chemically crosslinked collagen
sponge promotes soft tissue augmentation in the oral region by
fostering ingrowth of gingival cells while keeping volume after
loading and unloading of mechanical stresses.
For fostering ingrowth of gingival cells the chemically crosslinked
collagen sponge must have a high porosity (pore volume fraction) in
an appropriate diameter range for gingival fibroblasts to grow. It
has been found that this ingrowth is suitably fostered when the
sponge shows by mercury intrusion porosimetry interconnected pores
with a median pore diameter between 50 and 90 .mu.m and at least
80%, preferably at least 90%, porosity with a pore diameter more
than 10 .mu.m. The chemically crosslinked sponge with such a
distribution of pores is suitably prepared by a process comprising
mixing before crosslinking in appropriate proportions a slurry of
collagen fibres from the membrane prepared from porcine or bovine
peritoneum as disclosed in the previous paragraph and a slurry of
collagen fibres prepared from porcine dermis as disclosed in the
previous paragraph.
The term "resilient" here means that the chemically crosslinked
collagen sponge is resistant to pressure, i.e. capable of regaining
a large part of its original volume after being submitted to
pressure in vitro or in vivo.
For keeping volume in the oral region the resilient resorbable
chemically crosslinked sponge must be able to withstand the complex
mechanical forces induced by mastication, tongue movement, speech
and tooth movement by acting as a scaffold that maintains tissue
volume during a sufficient time during the healing process after
implantation, generally about 3 months. It has been found that this
in vivo resilient behaviour of the implant is attained when, in an
in vitro mechanical test of cyclic compression at a temperature of
37.degree. C. of the collagen sponge wetted by a phosphate buffer
saline (PBS) solution designed to mimic the body fluids, the
thickness retention in respect to the initial thickness is at least
70%, preferably at least 80%, more preferably at least 85%, or the
hysteresis retention in respect of the first loading is less than
55%, preferably less than 45%, after 49 cycles of compression to a
pressure of 12.1 kPa.
It has been found that the above in vitro thickness retention of at
least 70% and hysteresis retention of less than 55% combined with
in vivo healing without excessive inflammation or dehiscence is
attained when the sponge shows an onset temperature from 45 to
57.degree. C. and a density in dry state from 50 to 65
mg/cm.sup.3.
The onset temperature is measured by DSC on the collagen sponge
wetted with a buffer solution according to US Pharmacopia standard:
Ph. Eur. 2.2.34, USP <891> (buffer composition for 1 litre of
water: 8 g sodium chloride, 0.2 g potassium phosphate, 1.15 g
sodium phosphate and 0.2 g potassium chloride; start temperature
15.degree. C., end temperature 90.degree. C., heating rate
5.degree. C./min). This parameter reflects the crosslinking degree
of the sponge. The onset temperature is closely linked to the
sponge in vitro resistance to cyclic compression (thickness
retention or hysteresis retention in the mechanical test of cyclic
compression), in vivo resilience (keeping of tissue volume during a
sufficient time during the healing process after implantation) and
good integration into the surrounding tissues (no excessive
inflammation or dehiscence).
The required in vitro resistance to cyclic compression and the in
vivo resilience combined with in vivo healing without without
excessive inflammation or dehiscence can be attained when the onset
temperature is from 45 to 57.degree. C., preferably from 46 to
53.degree. C. When the onset temperature is below 46.degree. C.,
the in vitro resistance to cyclic compression and the in vivo
resilience may not be sufficient. When the onset temperature is
above 57.degree. C., there is a substantial risk of adverse events
such as excessive inflammation and/or dehiscence appearing after
implantation.
The density in dry state, measured by weighing and measuring the
volume of the collagen sponge after extensive lyophilisation (as
described in detail below), is another essential or critical
parameter for reaching the required in vitro resistance to cyclic
compression and the in vivo resilience combined with in vivo
healing without without excessive inflammation or dehiscence. Those
features can be attained when the density in dry state is from 50
to 65, preferably from 50 to 60 mg/cm.sup.3. When the density in
dry state is below 50 mg/cm.sup.3, the in vitro resistance to
cyclic compression and the in vivo resilience may not be
sufficient. When the density in dry state is above 65 mg/cm.sup.3,
there is a risk of adverse events such as excessive inflammation
and/or dehiscence appearing after implantation.
The term "resorbable" here means that the chemically crosslinked
collagen sponge is capable of being resorbed in vivo notably
through the action of collagenases and elastases. A controlled in
vivo resorbability of the chemically crosslinked collagen sponge is
essential to healing without excessive inflammation or dehiscence.
The enzymatic degradation test using collagenase from Clostridium
histolicum described in detail below gives an excellent prediction
of the in vivo resorbability.
In that test, for all samples of the sterile resilient resorbable
chemically crosslinked collagen sponge according to the invention
that in vivo showed interesting volume retention and healing
without adverse advents such as excessive inflammation or
dehiscence, the collagen was completely degraded in 3 to 5 hours.
The above resilient resorbable chemically crosslinked collagen
sponge is suitably prepared from tissues of natural origin by a
process comprising freeze drying and chemical crosslinking.
Appropriate tissues of natural origin include porcine or bovine
peritoneum or pericardium membranes, porcine or bovine placenta
membrane and porcine or bovine SIS or dermis. Preferably the
tissues of natural origin include porcine or bovine peritoneum
membrane and porcine dermis. The above process comprising freeze
drying and chemical crosslinking is generally followed by a
sterilization step, which is suitably .gamma. irradiation or X-ray
sterilization.
The chemical crosslinking may be performed using any
pharmaceutically acceptable crosslinking agent capable of giving to
the resilient resorbable chemically crosslinked collagen sponge the
required thickness retention in respect to the initial thickness or
hysteresis retention in respect to the first loading in the cyclic
compression test. Suitable such crosslinking agents include
gluteraldehyde, formaldehyde, acetaldehyde, 1,4-butane diglycidyl
ether (BDDGE), N-sulfosuccinimidyl-6-(4'-azido-2'-nitrophenylamino)
hexanoate, hexamethylene diisocyanate (HMDC), cynamide,
diphenylphosphorylazide, genipin, EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and a mixture of
EDC and NHS (N-hydoxysuccinimide). Small amounts or traces of the
unreacted crosslinking agent or typical direct reaction products
thereof can usually be detected in the resilient resorbable
chemically crosslinked collagen sponge.
Preferably the chemical crosslinking is performed using a
crosslinking agent selected from gluteraldehyde, EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and a mixture of
EDC and NHS (N-hydoxysuccinimide). Interesting prototypes of
resilient resorbable chemically crosslinked collagen sponges
according to the invention have indeed been prepared using each of
those crosslinking agents.
More than 1000 different prototypes of collagen sponges have been
prepared using as a crosslinking agent EDC or a mixture of EDC and
NHS and tested in various in vitro tests and/or in vivo animal
tests notably in mice, rats, rabbits and dogs. Preferably the
chemical crosslinking is performed using one of those two
crosslinking agents.
The resilient resorbable collagen sponge of the invention has been
notably tested in: an animal study involving measurement of mucosa
volume gain by implantation into chronic defects of mandibles of
dogs in comparison with the gold standard SCTG (Subepithelial
Connective Tissue Graft), and a clinical study to investigate its
performance and safety in tissue augmentation procedures to gain
mucosal thickness around dental implants in the oral cavity in
comparison with the gold standard for soft tissue volume
augmentation SCTG (Subepithelial Connective Tissue Graft).
In both of those studies the resilient resorbable chemically
crosslinked collagen sponge of the invention showed after
3-month-implantation an excellent integration into the surrounding
tissues without excessive inflammation or dehiscence, the same
safety and the same (i.e. not statistically different) soft tissue
volume retention as SCTG.
The above resilient resorbable chemically crosslinked collagen
sponge may be prepared by a process comprising the steps of: (a)
Submitting a porcine or bovine peritoneum or pericardium membrane
to a basic treatment in a sodium hydroxide solution at a pH above
12, an acid treatment in a hydrochloric solution of pH of 1 to 3, a
dehydrating treatment with a water soluble organic solvent and a
degreasing treatment with an organic solvent, milling the dry
membrane obtained with a cutting mill, sieving through a 0.5-2 mm
sieve and suspending the powder obtained in an acidified water
solution of pH from 2.5 to 3.5, such as to obtain a slurry of
collagen fibres, (b) Submitting grinded bovine or porcine dermis to
a dehydrating treatment with a water soluble organic solvent, a
degreasing treatment with an organic solvent, a basic treatment in
a strong inorganic base at a pH above 12, an acid treatment in a
strong inorganic acid at a pH from 0 to 1, rinsing with water and
suspending the collagen fibres, freeze-drying, cleaning the dried
collagen fibres with an organic solvent and grinding the cleaned
dried fibres in an acidified solution of pH from 3 to 4, such as to
obtain a slurry of collagen fibres, (c) Mixing 3.5 to 4.5 parts of
the slurry of collagen fibres obtained in (a) with 0.5 to 1.5 parts
of the slurry of collagen fibres obtained in (b), such as to obtain
a resulting slurry, (d) Freeze-drying the resulting slurry obtained
in (c) and crosslinking the freeze-dried product in a solution
containing a crosslinking agent, washing with water and
freeze-drying, and (e) Optionally sterilizing the freeze-dried
product obtained in (d) by .gamma. irradiation or X-ray
irradiation.
Step (a) may be performed similarly to the process described in
"Example" of EP-B1-1676592 by submitting the peritoneal membranes
from young calves or young pigs to washing with water, a basic
treatment with 2% sodium hydroxide solution, washing with water, an
acid treatment in a 0.5% hydrochloric solution, washing with water
until a pH of 3.5 is obtained, shrinking the material with 7%
saline solution, washing with water, dehydrating with acetone and
degreasing with n-hexane, milling the dry membrane obtained with a
cutting mill, sieving through a 0.5-2 mm sieve and suspending the
powder obtained in an acidified water solution of pH from 2.5 to
3.5, such as to obtain a slurry of porcine or bovine peritoneum
collagen fibres.
Step (a) is conveniently performed by milling the sterile membrane
Geistlich Bio-Gide.RTM. (obtainable from Geistlich Pharma A.G.,
Switzerland) with a cutting mill, sieving through a 0.5-2 mm sieve
and suspending the powder obtained in an acidified water solution
of pH from 2.5 to 3.5, such as to obtain a slurry of porcine
peritoneum collagen fibres.
Preferably the powder obtained after milling with a cutting mill is
sieved through a 0.5-1 mm sieve.
Step (b) may be performed similarly to the process disclosed in
Example 7 of WO 2012/084214 by submitting grinded porcine rinds to
a dehydrating treatment with a water soluble organic solvent such
as an alcohol or a ketone, a degreasing treatment with an organic
solvent such a dichloroethane or methylene chloride, a basic
treatment in a strong inorganic base at a pH above 12 for a period
of 6 to 24 hours, an acid treatment in a strong inorganic acid at a
pH from 0 to 1 for a period of 1 to 12 hours, rinsing with water
and suspending the collagen fibres in the presence of a swelling
regulator, freeze-drying, cleaning the dried collagen fibres with
different organic solvents such as alcohols, ethers, ketones and
chlorinated hydrocarbons and grinding in a colloid mill the cleaned
dried fibres in an acidified solution of pH from 3 to 4, such as to
obtain a slurry of porcine dermis collagen fibres.
The (w/w) % collagen in the slurry of collagen fibres prepared in
step (a) and (w/w) % collagen in the slurry of collagen fibres
prepared in step (b) play a role in setting the density in dry
state of the resilient resorbable chemically crosslinked collagen
sponge. Indeed, the latter mainly depends on one side on the (w/w)
% collagen of the resulting slurry of collagen fibres obtained in
step (c) by mixing 1.5 to 4.5 parts of the slurry of collagen
fibres obtained in (a) with 0.5 to 1.5 parts of the slurry of
collagen fibres obtained in (b) and on the other side on the
conditions of the crosslinking reaction in step (d).
To achieve for the resilient resorbable chemically cross-linked
collagen sponge the required density in dry state of 50 to 65
mg/cm.sup.3, the slurry of collagen fibres prepared in step (a)
contains generally from 2.0 to 4.5, preferably 2.5 to 3.75 (w/w) %
collagen and the slurry of collagen fibres prepared in step (b)
contains generally from 3.0 to 7.0, preferably 4.0 to 6.0 (w/w) %
collagen.
Step (c) comprises mixing 3.5 to 4.5 weight parts of the slurry of
collagen fibres obtained in (a) with 0.5 to 1.5 weight parts of the
slurry of collagen fibres obtained in (b), such as to obtain a
resulting slurry.
This mixing step of appropriate proportions of two different
slurries of collagen fibres coming from different porcine or bovine
tissues and having been subjected to different treatments including
different grinding procedures (using a cutting mill for step (a)
and a colloid mill for step (b)) giving collagen fibre particles of
different sizes, is a convenient method for attaining the desired
porosity distribution or spectrum of the resilient resorbable
chemically crosslinked collagen sponge, namely interconnected pores
with a median pore diameter between 50 and 90 .mu.m and at least
80%, preferably at least 90% porosity with a pore diameter more
than 10 .mu.m as determined by mercury intrusion porosimetry.
The resulting slurry generally contains 3.0 to 6.5 (w/w) %,
preferably 3.5 to 6.0 (w/w) % collagen.
Step (d) comprises freeze-drying the resulting slurry obtained in
(c), crosslinking the freeze-dried product in a solution containing
a crosslinking agent, washing with water and freeze-drying.
Freeze-drying before and after the crosslinking step is generally
performed at a temperature below -10.degree. C.
The crosslinking agent is suitably selected from the group
consisting of gluteraldehyde, EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and a mixture of
EDC and NHS (N-hydoxysuccinimide). Other crosslinking agents known
for crosslinking collagen such as formaldehyde, acetaldehyde,
1,4-butane diglycidyl ether (BDDGE),
N-sulfosuccinimidyl-6-(4'-azido-2'-nitrophenylamino) hexanoate,
hexamethylene diisocyanate (HMDC), cynamide,
diphenylphosphorylazide or genipin may also be used.
When the crosslinking agent is gluteraldehyde, the sponge obtained
after freeze-drying is suitably chemically cross-linked in a
phosphate buffer solution of pH 7.0 to 7.5 containing 0.01 to
0.10%, preferably 0.04 to 0.06% gluteraldehyde. The chemically
crosslinked sponge may be successively washed with water, 1-3 M
NaCl solution, 0.05-0.15 M Na.sub.2HPO.sub.4 solution and water,
before being freeze-dried.
When the crosslinking agent is EDC, the sponge obtained after
freeze-drying is suitably first submitted to a dehydrothermal
treatment at a temperature above 110.degree. C., then chemically
crosslinked in a buffer solution containing 0.05-0.15 M MES
(2-(N-morpholino)-ethanesulfonic acid) or 0.05-0.15 M acetic acid
and 2-20% (w/w) of an alcohol selected from the group consisting of
methanol, ethanol, n-propanol, isopropanol and butanol, with
0.03-0.80, preferably 0.2-0.4 g EDC per g collagen, for a period of
1 to 8 hours. The (w/w) ratio of collagen to the reaction medium
(the above buffer solution) is generally from 1/10 to 1/100,
preferably from 1/20 to 1/50. When the alcohol is ethanol, it is
suitably present at 3-7% (w/w) in the buffer solution. The
chemically crosslinked collagen sponge may be washed first with
0.05-0.15 M Na.sub.2HPO.sub.4 solution, a 0.5-3 M NaCl solution,
then with water before being freeze-dried.
When the crosslinking agent is a mixture of EDC and NHS, the sponge
obtained after freeze-drying is suitably chemically crosslinked in
a buffer solution containing 0.1-0.3 M MES
(2-(N-morpholino)-ethanesulfonic acid) or 0.1-0.3 M acetic acid and
10-70% (w/w) alcohol selected from the group consisting of
methanol, ethanol, n-propanol, isopropanol and butanol, with
0.01-0.60, preferably 0.05-0.2 g EDC and 0.01-0.6, preferably
0.05-0.2 g NHS, per g collagen, for a period of 1 to 8 hours. The
molar ratio of EDC to NHS is generally from 4 to 0.5, preferably
from 2 to 1. The (w/w) ratio of collagen to the reaction medium
(the above buffer solution) is generally from 1/10 to 1/100,
preferably from 1/20 to 1/50. When the alcohol is ethanol, it is
suitably present at 40-60% (w/w) in the buffer solution. The
chemically crosslinked collagen sponge may be washed first with
0.05-0.15 M Na.sub.2HPO.sub.4 solution, then with water before
being freeze-dried.
For each mixture of slurries of collagen fibres obtained in (c) the
skilled person will be in a position based on the teaching of the
present application, using only common general knowledge of the art
and routine experimentation, to find the crosslinking agent and the
crosslinking conditions such as to obtain a resilient resorbable
chemically cross-linked collagen sponge according to the invention
having the specified onset temperature and density in dry
state.
The following has thus e.g. been found by routine experimentation
for collagen slurries containing 3.0 to 6.5 (w/w) % collagen: When
the crosslinking agent is EDC: the onset temperature is increased,
for a rise of the concentration of EDC in the buffer solution, the
ratio of EDC to collagen, the (w/w) ratio of the reaction medium to
collagen or the % of alcohol in the buffer solution. the density in
dry state is decreased (more shrinkage of collagen) for a rise of
the % of alcohol in the buffer solution. When the crosslinking
agent is a mixture EDC and NHS: the onset temperature is increased,
for a rise in the concentration of the crosslinking agent in the
buffer solution, the (w/w) ratio of the crosslinking agent
(EDC+NHS) to collagen, ratio of EDC to NHS, the (w/w) ratio of the
reaction medium to collagen or the % of alcohol in the buffer
solution. the density in dry state is decreased (more shrinkage of
collagen) for a rise of the % of alcohol in the buffer
solution.
The freeze-dried resilient resorbable chemically cross-linked
collagen sponge obtained at the end of step (d) will generally be
submitted to step (e) of sterilization by .gamma. irradiation or
X-ray irradiation. That step may not be necessary if the mixture of
collagen slurries obtained in step (c) is already aseptic and step
(d) is performed under aseptic conditions.
The in vitro cyclic compression test and enzymatic degradation test
using collagenase from Clostridium histolyticum, which are
described in detail below, are very useful in predicting the in
vivo behaviour of the chemically cross-linked sponge after
implantation into the oral cavity, notably its capacity of keeping
volume and healing without adverse events such as excessive
inflammation or dehiscence.
The invention also relates to the above process for preparing the
resilient resorbable chemically crosslinked collagen sponge.
The invention also concerns the above resilient resorbable
chemically crosslinked collagen sponge for use as an implant for
the oral cavity, the use of that resilient resorbable chemically
crosslinked collagen sponge for preparing an implant for the oral
cavity and a method of augmenting soft tissue volume in the oral
region, notably by fostering the ingrowth of gingival cells while
keeping volume under mechanical stresses, which comprises
implanting into the oral cavity the above resilient resorbable
chemically cross-linked collagen sponge.
The following experimental methods, tests and Examples illustrate
the invention without restricting its scope.
Test for Determination of the Density of the Resilient Resorbable
Chemically Crosslinked Collagen Sponge in Dry State
The resilient resorbable chemically crosslinked collagen sponge
samples were introduced into tared plastic tubes which are dried in
a freeze-drier for at least 2 hours at a temperature of 20.degree.
C. and a pressure below 0.5 mbar. The tubes with dried samples were
weighed and the net weights of the samples in dry state
calculated.
The length, width and height of the resilient resorbable chemically
crosslinked collagen sponge samples were measured by using an
electrical slide gauge, by applying enough contact pressure such
that the samples are loosely fixed (i.e. fixed to resist the force
caused by their weight but apt to move when is force is increased
about 10-fold). The volumes of the samples in dry state were
calculated. The density of the resilient resorbable chemically
crosslinked collagen sponge in dry state (weight over volume) was
then calculated for each sample.
Cyclic Compression Test
The % of initial thickness and hysteresis in respect to the first
loading after 49 cycles of compression to a pressure of 12.1 kPa
were measured using a mechanical compression machine, namely Z2.5
material compression machine manufactured by Zwick Roell, using the
program Test Expert II.
The measurements were performed submerged in PBS at 37.degree. C.
on sterile, resilient resorbable chemically crosslinked collagen
sponge samples which had been incubated for 2 hours at 37.degree.
C. in a PBS solution of pH 7.4 (prepared by dissolving 80.0 g NaCl,
2.0 g KCl, 17.7 g Na.sub.2HPO.sub.4 and 2.4 g KH.sub.2PO.sub.4 in
1000 ml water, diluting ten times the solution in water and
adjusting the pH with HCl to 7.4).
Samples were subjected to a total of 49 cycles of loading between
0.5 and 12.1 kPa at a strain rate of 33% of initial height per min,
analysis starting at a pre-pressure of 0.25 kPa.
The initial height at 0.5 kPa pressure was used to calculate the
retention of initial height after 49 cycles of loading and
unloading. The "hysteresis in respect to the first loading" is the
percentage work which was dissipated during unloading using the
work (W.sub.1,loading in Nm) between 0.5 and 12.1 kPa of the first
loading and the work from the 49.sup.th unloading cycle
(W.sub.49,unloading in Nm) according equation XY:
" ".times..times..times. ##EQU00001##
The program Test Expert or Excel calculates the % of retention of
initial thickness and the % of retention of initial hysteresis
after 49 cycles of compression to a pressure of 12.1 kPa.
The FIGURE shows the typical result of a cyclic compression
test.
For samples of the resilient resorbable chemically cross-linked
collagen sponge according to the invention that in vivo showed
interesting volume retention and healing without excessive
inflammation or dehiscence: the height or thickness retention in
respect of the initial height was at least 70%, preferably at least
80%, more preferably at least 85%, after 49 cycles of compression
to 12.1 kPa, and the hysteresis retention in respect to the first
loading after 49 cycles of compression to 12.1 kPa was less than
55%, preferably less than 45%. Enzymatic Degradation Test Using
Collagenase from Clostridium histolyticum
In the human body collagens are degraded by human tissue
matrix-metalloproteinase (MMP), cathepsins and putatively by some
serine proteinases. Best studied are the MMPs where collagenases
(notably MMP-1, MMP-8, MMP-13 and MMP-18) are the most important
enzymes for direct collagen degradation (Lauer-Fields et al. 2002
Matrix metalloproteinases and collagen catabolism in
Biopolymers--Peptide Science Section and Song et al. 2006 Matrix
metalloproteinase dependent and independent collagen degradation in
Frontiers in Bioscience).
Collagenase capability to degrade collagen tissues and membranes
depends on the substrate flexibility and collagen type, MMP active
sites and MMP exosites.
Collagenases align at the triple helical collagen, unwind it and
subsequently cleave it (Song et al. 2006, see above).
With the view of overcoming differences in degradation between the
different collagen types, collagenase degradation of collagen is
often assessed using collagenase from Clostridium histolyticum
which has a high catalytic speed (Kadler et al. 2007 Collagen at a
glance in J Cell Sci). Generally, a natural collagen product
degrades faster than a chemically cross-linked collagen
product.
In this test the collagen products (samples of resilient resorbable
chemically crosslinked collagen sponge according to the invention
were incubated at 37.degree. C. with 50 units/ml from Clostridium
histolyticum (one unit being defined as liberating peptides from
collagen from bovine Achilles tendon equivalent in ninhydrin color
to 1.0 micromole of leucine in 5 hours at pH 7.4 at 37.degree. C.
in the presence of calcium ions) in a calcium containing
Tris-buffer and the degradation of the collagen matrix was measured
visually and with the "DC Protein Assay" from Bio-Rad Laboratories
(Hercules, USA, Order Nr. 500-0116) using Collagen Type I as
reference material. The collagen concentration was determined using
a microwellplate spectrometer (Infinite M200, available from
Tecan).
For samples of the resilient resorbable chemically cross-linked
collagen sponge according to the invention that in vivo showed
healing without excessive inflammation or dehiscence, the collagen
was completely degraded (no collagen fibre detectable by visual
inspection) within 3 to 5 hours.
EXAMPLE 1
Preparation of a Slurry of Collagen Fibres Derived from Porcine
Peritoneum
The peritoneal membranes from young pigs were completely freed from
flesh and grease by mechanical means, washed under running water
and treated with 2% NaOH solution for 12 hours. The membranes were
then washed under running water and acidified with 0.5% HCl. After
the material had been acidified through its entire thickness (about
15 min) the material was washed until a pH of 3.5 was obtained. The
material was then shrunk with 7% saline solution, neutralised with
1% NaHCO.sub.3 solution and washed under running water. The
material was then dehydrated with acetone and degreased with
n-hexane.
The material was dried using ethanol ether and milled with a
cutting mill (e.g. Pulverisette 25 from Fritsch: see
fetsch.de./produkte/mahlen/schneidmuehlen/pulverisette-25 or SM300
from Retsch: retsch.de/de/produkte/zerkleinern/schneidmuehlen)
which includes a trapezoidal sieve of 0.5 to 1.0 mm.
A 4% (w/w) slurry of collagen fibres and a 6% (w/w) slurry of
collagen fibres were prepared by suspending adequate amounts of the
dried powder in water and adjusting the pH to 2.6 with 10 mM
hydrochloric acid.
EXAMPLE 2
Preparation of a Slurry of Collagen Fibres Derived from a Sterile
Geistlich Bio-Gide.RTM. Membrane
A Geistlich Bio-Gide.RTM. membrane (available from Geistlich Pharma
AG, CH-6110, Switzerland) was dried and milled with a cutting mill
which includes a trapezoidal sieve of 0.5 to 1.0 mm. A 4% (w/w)
collagen slurry of collagen fibres and a 6% (w/w) collagen slurry
of collagen fibres were prepared by suspending adequate amounts of
the dried powder in water and adjusting the pH to 2.6 with 10 mM
hydrochloric acid.
EXAMPLE 3
Preparation of a Slurry of Collagen Fibres Derived from Pig
Dermis
Porcine hides were ground in a meat grinder to pieces of 1 to 20
mm. The water was removed using a water soluble solvent such as an
alcohol or a ketone. The collagen fibres were defatted using a
chlorinated hydrocarbon such as dichloroethane or methylene
chloride or a non-chlorinated hydrocarbon such as hexane or
toluene. After removing the solvent the collagen was treated with a
strong inorganic base at a pH above 12 for a period of 6 to 24
hours and treated with a strong inorganic acid at a pH of 0 to 1
for a period of 1 to 12 hours. The excess acid was removed by
rinsing with water and the suspension was homogenized by colloid
milling to a 0.5 to 2% homogenous suspension of collagen fibres in
the presence of a swelling regulator such as an inorganic salt. The
suspension was dried by freeze-drying and the dry collagen fibres
were successively cleaned with different organic solvents such as
alcohols, ethers, ketones and chlorinated hydrocarbons, the
solvents being then evaporated under vacuum to a solvent residue of
less than 1% (w/w).
A 2.5% (w/w) collagen slurry of collagen fibres and a 3.75% (w/w)
collagen slurry of collagen fibres were prepared by finely grinding
by colloid milling adequate amounts of the cleaned dry fibres
obtained above with water at a pH of 3.4.
EXAMPLE 4
Preparation of a Resilient Resorbable Collagen Sponge Chemically
Crosslinked with EDC
4 parts of the 4% (w/w) collagen slurry of collagen fibres obtained
in Example 1 or Example 2 were mixed with 1 part of the 2.5% (w/w)
collagen slurry of collagen fibres obtained in Example 3 and poured
into molds of 8.times.25.times.25 mm. The resulting 3.7% slurry of
collagen fibres was dried by freeze-drying at -45.degree. C.
The dried collagen sponges were then dehydrothermally treated at
120.degree. C. for 24 hours under reduced pressure (less than 200
mbar).
The collagen sponges were then chemically crosslinked in a buffer
solution containing 0.1 M MES (2-(N-morpholino)-ethanesulfonic
acid) and 5% ethanol at a pH of 5.5 with 0.3 g EDC
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) per g collagen,
under agitation at room temperature for a period of 120 min.
The chemically crosslinked collagen sponges were washed first with
0.10 M Na2HPO4 solution, 1M NaCl solution, 2M NaCl solution, then
with water and freeze-dried at -45.degree. C.
The dried chemically crosslinked collagen sponges were
gamma-sterilized at 30 kGy. The measured onset temperature and
density in dry state of the sterilized chemically crosslinked
collagen sponges were 47.degree. C. and 64 mg/cm.sup.3,
respectively.
After 49 cycles of compression to a pressure of 12.1 kPa in PBS at
37.degree. C., the sterilized chemically crosslinked collagen
sponges showed a retention of 87% of its initial thickness and 41%
of the initial hysteresis.
Mercury intrusion porosimetry showed for the sterilized chemically
crosslinked collagen sponges a median pore diameter of 88 .mu.m and
95% porosity with a pore diameter more than 10 .mu.m.
The enzymatic degradation test using collagenase from Clostridium
histolyticum showed a complete degradation of collagen within 3.25
hours.
EXAMPLE 5
Preparation of a Resilient Resorbable Collagen Sponge Chemically
Crosslinked with a Mixture of EDC and NHS
Four parts of the 6% (w/w) slurry of collagen fibres obtained in
Example 1 or Example 2 were mixed with one part of the 3.75% (w/w)
slurry of collagen fibres obtained in Example 3 and poured into
molds of a height of 6 mm. The resulting 5.55% (w/w) collagen
slurry of collagen fibres was dried by freeze drying at -10.degree.
C. These sponges were chemically crosslinked in a solution
containing 0.2 M MES (2-(N-morpholino)-ethanesulfonic acid) and 50%
w/w ethanol at a pH of 5.5 with 0.1 g EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) per gram collagen
and 0.1 g NHS (N-hydoxysuccinimide) per gram collagen, under
agitation at room temperature for a period of 120 min. The
chemically crosslinked sponges were washed first with 0.1 M
Na.sub.2HPO.sub.4 solution, 1M NaCl solution, 2M NaCl solution,
then with water and freeze dried at -10.degree. C.
The dried chemically crosslinked collagen sponges were sterilized
by .gamma.-irradiation at 26 kGy.
The measured onset temperature and density in dry state of the
sterilized chemically crosslinked collagen sponges were 52.degree.
C. and 59 mg/cm.sup.3, respectively. After 49 cycles of compression
to a pressure of 12.1 kPa in PBS at 37.degree. C., the sterilized
chemically crosslinked collagen sponges showed a retention of 90%
of its initial thickness and 38% of the hysteresis in respect of
the first loading. Mercury intrusion porosimetry showed for the
sterilized chemically cross-linked collagen sponges a median pore
diameter of 69.1 .mu.m and 93.1% porosity with a pore diameter more
than 10 .mu.m.
The enzymatic degradation test using collagenase from Clostridium
histolyticum showed a complete degradation of collagen within 3.5
hours.
EXAMPLE 6
Preparation of a Resilient Resorbable Collagen Sponge Chemically
Crosslinked with a Mixture of EDC and NHS (without a Sterilization
Step)
Four parts of the 6% (w/w) slurry of collagen fibres obtained in
Example 2 were mixed with one part of the 3.75% (w/w) slurry of
collagen fibres obtained in Example 3 and poured into molds of a
height of 6 mm. The resulting 5.55% (w/w) collagen slurry of
collagen fibres was dried by freeze drying at -10.degree. C.
These sponges were chemically crosslinked in a solution containing
0.2 M MES (2-(N-morpholino)-ethanesulfonic acid) and 50% w/w
ethanol at a pH of 5.5 with 0.01 g EDC
(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) per gram collagen
and 0.01 g NHS (N-hydoxysuccinimide) per gram collagen, under
agitation at room temperature for a period of 120 min. The
chemically crosslinked sponges were washed first with 0.1 M
Na.sub.2HPO.sub.4 solution, 1M NaCl solution, 2M NaCl solution,
then with water and freeze dried at -10.degree. C.
The measured onset temperature and density in dry state of the
chemically crosslinked collagen sponges were 57.degree. C. and 57
mg/cm.sup.3 respectively.
After 49 cycles of compression to a pressure of 12.1 kPa in PBS at
37.degree. C., the chemically crosslinked collagen sponges showed a
retention of 80% of its initial thickness.
Mercury intrusion porosimetry showed for the chemically crosslinked
collagen sponges a median pore diameter of 71.0 .mu.m and 94.0%
porosity with a pore diameter more than 10 .mu.m.
EXAMPLE 7
Preparation of a Resilient Resorbable Collagen Sponge Chemically
Crosslinked with Glutaraldehyde
Four parts of the slurry of collagen fibres obtained in Example 1
were mixed with one part of the slurry of collagen fibres obtained
in Example 3 and poured into molds of a height of 6 mm. The
collagen slurry was dried by freeze drying at minus 45.degree. C.
These sponges were chemically crosslinked in a sodium phosphate
buffer (pH 7.0-7.5) containing 0.05% (w/w) glutaraldehyde at
10.degree. C. for 60 min. The chemically crosslinked collagen
sponges were successively washed with water, 2 M NaCl solution and
0.1 M Na.sub.2HPO.sub.4 solution. After the final rinse with water
the sponges were freeze dried at -45.degree. C.
The chemically crosslinked collagen sponges were sterilized by
.gamma.-irradiation at 25 kGy.
The measured onset temperature and density in dry state of the
sterilized chemically crosslinked collagen sponges were
respectively 51.degree. C. and 52 mg/cm.sup.3.
After 49 cycles of compression to a pressure of 12.1 kPa at
37.degree. C., the sterilized chemically crosslinked collagen
sponges in PBS showed a retention of 74% of their initial thickness
and 48% hysteresis in respect of the first loading.
Mercury intrusion porosimetry showed for the sterilized chemically
crosslinked collagen sponges a median pore diameter of 63.7 .mu.m
and 92.7% porosity with a pore diameter more than 10 .mu.m.
The enzymatic degradation test using collagenase from Clostridium
histolyticum showed a complete degradation of collagen within 4.5
hours.
* * * * *